FY2026 EPS Estimates for Harrow Lifted by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has increased its FY2026 earnings per share estimate for Harrow, Inc. to $2.39, up from a prior estimate of $2.12, maintaining an "Overweight" rating with a price target of $76.00.
• Harrow's stock has received multiple "buy" ratings from various brokerages, with a consensus rating of "Buy" and an average target price of $64.67.
• The company reported a quarterly earnings per share of $0.24, exceeding analyst estimates of $0.01, though it had a revenue of $63.74 million, slightly below the consensus of $64.23 million.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Analysts at Cantor Fitzgerald increased their FY2026 earnings per share estimates for shares of Harrow in a report released on Wednesday, August 13th. Cantor Fitzgerald analyst S. Seedhouse now anticipates that the company will earn $2.39 per share for the year, up from their previous estimate of $2.12. Cantor Fitzgerald currently has a "Overweight" rating and a $76.00 price target on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share.

Several other brokerages have also weighed in on HROW. Zacks Research raised Harrow from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. William Blair began coverage on Harrow in a research report on Tuesday, June 10th. They issued an "outperform" rating on the stock. HC Wainwright increased their target price on Harrow from $60.00 to $64.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. Finally, BTIG Research raised their price target on Harrow from $62.00 to $63.00 and gave the company a "buy" rating in a report on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $64.67.

Harrow Stock Performance

NASDAQ HROW traded down $0.09 during trading hours on Thursday, hitting $38.23. The company had a trading volume of 407,120 shares, compared to its average volume of 482,327. Harrow has a fifty-two week low of $20.85 and a fifty-two week high of $59.23. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78. The business has a fifty day simple moving average of $33.34 and a 200-day simple moving average of $28.92. The firm has a market cap of $1.41 billion, a P/E ratio of -152.38 and a beta of 0.41.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.23. The business had revenue of $63.74 million for the quarter, compared to analyst estimates of $64.23 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Harrow has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in Harrow during the fourth quarter worth about $25,000. Quarry LP acquired a new position in Harrow during the first quarter worth about $32,000. Raymond James Financial Inc. acquired a new position in Harrow during the second quarter worth about $48,000. Tower Research Capital LLC TRC grew its holdings in Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after acquiring an additional 1,462 shares during the period. Finally, Aquatic Capital Management LLC acquired a new position in shares of Harrow in the 4th quarter valued at $78,000. 72.76% of the stock is owned by institutional investors and hedge funds.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.